Literature DB >> 27679435

Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications.

Moniek P M de Maat1, Marianne van Schie2, Cornelis Kluft3, Frank W G Leebeek2, Piet Meijer3.   

Abstract

BACKGROUND: Levels of hemostasis factors vary between and within individuals as a result of genetic and environmental factors and analytical variation of the assays. The current state of the art for defining analytical precision requirements for analytical testing is based on this between- and within-individual (biological) variation. However, information on biological variation in hemostasis variables is still limited.The aim of this study was to determine the biological variation of coagulation variables involved in thrombosis and bleeding to provide a recommendation for performance specifications and to assess whether hemostasis assays fulfill the recommendation.
METHODS: We performed a longitudinal study by repeated blood sampling (in total 13 times over a 1-year period) in 40 healthy individuals and measured prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, antithrombin, factor VIII, factor IX, von Willebrand factor (VWF), protein C, and protein S. We evaluated the effect of the biological variation on parameters of analytical variation and propose required performance specifications.
RESULTS: Biological variation was highly different for various hemostasis variables: the within-subject variation ranged from 2.6% (PT) to 25.6% [VWF collagen binding (CB) activity], the between-subject variation varied from 4.1% (PT) to 31.2% (VWF:ristocetin cofactor acitivity), and the assay variation from 1.3% (PT) to 12.9% (VWF:CB).
CONCLUSIONS: With the reagents and analyzers used in this study, most of the hemostasis tests variables fulfill the current quality criteria for diagnosis and monitoring of routine hemostasis assays.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Year:  2016        PMID: 27679435     DOI: 10.1373/clinchem.2016.261248

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.

Authors:  Frank Driessler; Maricel G Miguelino; Glenn F Pierce; Robert T Peters; Jurg M Sommer
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

2.  ADAMTS-13 and bleeding phenotype in von Willebrand disease.

Authors:  Johan Boender; Angelique Nederlof; Karina Meijer; Evelien P Mauser-Bunschoten; Marjon H Cnossen; Karin Fijnvandraat; Johanna G van der Bom; Joke de Meris; Britta A P Laros-van Gorkom; Karin P M van Galen; Jeroen Eikenboom; Moniek P M de Maat; Frank W G Leebeek
Journal:  Res Pract Thromb Haemost       Date:  2020-10-31

3.  Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID-19, not entirely explaining the increased risk of thrombosis.

Authors:  Judith J de Vries; Chantal Visser; Lotte Geers; Johan A Slotman; Nadine D van Kleef; Coen Maas; Hannelore I Bax; Jelle R Miedema; Eric C M van Gorp; Marco Goeijenbier; Johannes P C van den Akker; Henrik Endeman; Dingeman C Rijken; Marieke J H A Kruip; Moniek P M de Maat
Journal:  J Thromb Haemost       Date:  2022-04-01       Impact factor: 16.036

4.  Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.

Authors:  Ferdows Atiq; Karina Meijer; Jeroen Eikenboom; Karin Fijnvandraat; Eveline P Mauser-Bunschoten; Karin P M van Galen; Marten R Nijziel; Paula F Ypma; Joke de Meris; Britta A P Laros-van Gorkom; Johanna G van der Bom; Moniek P de Maat; Marjon H Cnossen; Frank W G Leebeek
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.